Where we work

Assuming regional differences in HAT epidemiology that should be taken into account when developing diagnostic algorithms, WP2, WP3 and WP5 will be implemented simultaneously in West-Africa and in Central Africa. In West Africa, WP2 is implemented in Guinea and Côte d’Ivoire. WP3  in Côte d’Ivoire and Burkina Faso. Guinea still has active Human African Trypanosomiasis (HAT) transmission sites, and has the highest HAT prevalence in West-Africa. Côte d’Ivoire represents a country where cases are still detected but where elimination is almost achieved. In Burkina Faso, HAT is eliminated but imported cases can be detected. Specimens collected in Guinea, Côte d’Ivoire and Burkina Faso will be sent to the West African HAT reference laboratory based in Bobo Dioulasso, Burkina Faso. For Central Africa, DR Congo is chosen. DR Congo harbours most HAT cases, although the HAT epidemiology is heterogeneous. This country has HAT foci with active transmission while other foci are nearly eliminated. In DR Congo, WP2 will be conducted in 2 provinces, WP3 in 1 focus. For WP4 we will work with the HAT treatment centres in DR Congo where DNDi is conducting therapeutic trials on fexinidazole and oxaborole. Specimens will be sent to the HAT reference laboratory in Kinshasa, DR Congo.

Guinea (Implementation of WP2)

Implementation of WP2

Côte d’Ivoire (Implementation of WP2)

Implementation WP2

Côte d’Ivoire (Implementation of WP3)

Implementation WP3

Implementation of WP3, Reference lab in WP5

Implementation of WP3

DR. Congo: Implementation of WP2, WP3 & WP4. Reference lab in WP5.